Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,615.60
(
0.50%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
108.75
(
0.46%
)
Bitcoin
67,733.61
(
2.69%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biocqr post# 193371

Tuesday, 07/14/2015 10:39:51 AM

Tuesday, July 14, 2015 10:39:51 AM

Post# of 257302

(AGTC bearish argument)—AAVL has a lead in gene therapy directed at wet AMD for which AGTC is gearing up; AGTC will also be competing with its former partner Genzyme.

This is a lame argument, IMO. AGTC’s AMD program is essentially vaporware, as far as I can tell; I doubt it will ever enter clinical trials. In other words, if anyone thinks the (purported) AMD program is a material component of AGTC’s value, they’re mistaken.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today